Central beta-adrenoceptor sites and ouabain action.
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001794:Blood Pressure / Q000187:drug effects; D003994:Bucladesine / Q000494:pharmacology; D002395:Catecholamines / Q000378:metabolism; D002415:Cats; D002552:Cerebral Ventricles; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006584:Hexamethonium Compounds / Q000494:pharmacology; D006892:Hydroxydopamines / Q000494:pharmacology; D007267:Injections; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008738:Methyl Ethers / Q000494:pharmacology; D010042:Ouabain / Q000494:pharmacology*; D011807:Quinolizines / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000187:drug effects*; D013238:Stereotaxic Techniques; D013618:Tachyphylaxis / Q000139:chemically induced; D013806:Theophylline / Q000494:pharmacology; D014628:Vagotomy; D014630:Vagus Nerve / Q000502:physiology
D002395:Catecholamines; D006584:Hexamethonium Compounds; D006892:Hydroxydopamines; D008738:Methyl Ethers; D011807:Quinolizines; D011941:Receptors, Adrenergic; D010042:Ouabain; D003994:Bucladesine; D013806:Theophylline; D007545:Isoproterenol